Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

Tidepool today announced a new data integration with Abbott for the company's FreeStyle Libre continuous glucose monitors ...

Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) ...

--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a ...

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding ... Continuous ...

Now iLet Users Have a Choice of iCGMs to Customize Their Diabetes ManagementIRVINE, CA / ACCESSWIRE / October 30, 2024 / Beta ...

Tidepool collaborates with Abbott for seamless data integration ... to initiate the connection with their patients using FreeStyle Libre 2 and 3 systems in clinic or remotely.

We expect the company to post a mid-single-digit uptick in revenue, driven by higher FreeStyle Libre ... Abbott’s revenue of $10.4 billion in Q2 was up 4% y-o-y. The company reported a 10.2% ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations.

由于第三季度表现强劲，Abbott Laboratories提高了全年利润预期，这主要得益于其医疗设备（包括FreeStyle Libre血糖监测仪）的强劲销售。公司的医疗设备部门报告销售额为47.5亿美元，超过分析师平均预期的46.8亿美元。